Yukon-Kuskokwim Health Corporation, United States.
Centers for Disease Control & Prevention, United States.
Vaccine. 2023 May 26;41(23):3544-3549. doi: 10.1016/j.vaccine.2023.04.070. Epub 2023 May 1.
The population in rural southwest Alaska has been disproportionately affected by COVID-19. To assess the benefit of COVID-19 vaccines, we analyzed data from the regional health system. We estimated vaccine effectiveness (VE) during January 16-December 3, 2021, against symptomatic SARS-CoV-2 infection after a primary series or booster dose, and overall VE against hospitalization. VE of a primary series against symptomatic infection among adult residents was 91.3% (95% CI: 85.7, 95.2) during January 16-May 7, 2021, 50.3% (95% CI, 41.1%-58.8%) during July 17-September 24, and 37.0% (95% CI, 27.8-45.0) during September 25-December 3, 2021; VE of a booster dose during September 25-December 3, 2021, was 92.1% (95% CI: 87.2-95.2). During the overall study period, VE against hospitalization was 91.9% (95% CI: 85.4-95.5). COVID-19 vaccination offered strong protection against hospitalization and a booster dose restored protection against symptomatic infection.
阿拉斯加西南部农村地区的人口不成比例地受到了 COVID-19 的影响。为了评估 COVID-19 疫苗的效果，我们分析了区域卫生系统的数据。我们估计了 2021 年 1 月 16 日至 12 月 3 日期间，在接种完基础系列或加强针后，针对有症状的 SARS-CoV-2 感染的疫苗有效性（VE），以及针对住院的总体 VE。在 2021 年 1 月 16 日至 5 月 7 日期间，基础系列疫苗对成年居民有症状感染的 VE 为 91.3%（95%CI：85.7，95.2），在 7 月 17 日至 9 月 24 日期间为 50.3%（95%CI，41.1%-58.8%），在 9 月 25 日至 12 月 3 日期间为 37.0%（95%CI，27.8-45.0）；在 2021 年 9 月 25 日至 12 月 3 日期间，加强针的 VE 为 92.1%（95%CI：87.2-95.2）。在整个研究期间，疫苗对住院的保护率为 91.9%（95%CI：85.4-95.5）。COVID-19 疫苗接种为住院提供了强有力的保护，而加强针恢复了对有症状感染的保护。
